Sunday, March 29, 2026 – Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide)...
Sunday, March 29, 2026 – INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1...
Sunday, March 29, 2026 – South San Francisco, CA -- March 5, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493...
Sunday, March 29, 2026 – Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026 – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take effect later this month. Under the terms of the agreement, Hims...
Sunday, March 29, 2026 – NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and...
Sunday, March 29, 2026 – (MedPage Today) -- The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed.
In a...
Sunday, March 29, 2026 – A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It's a simple premise: What if something as small as a digital nudge could put someone on the path to healthier habits while taking GLP-1 medications?
Sunday, March 29, 2026 – (MedPage Today) -- GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients...
Sunday, March 29, 2026 – (MedPage Today) -- The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the...
Sunday, March 29, 2026 – (MedPage Today) -- Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered...